This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Glaucoma  • Alert me on articles by topic

Arch Ophthalmol. 2004;122:378-379.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Ocular Hypertension Treatment Study (OHTS), a landmark trial in glaucoma therapy, has definitively answered the question "Does lowering intraocular pressure (IOP) in persons with elevated IOP but no glaucoma damage reduce the incidence of glaucoma?", confirming what most ophthalmologists knew—that treatment works.

However, even the most ardent supporters of treatment to lower IOP would concede that the results of the study do not suggest that all persons with ocular hypertension should be treated.^1-2 After all, only 9.5% of the subjects who were observed without therapy developed glaucoma during a mean follow-up period of 6 years. As the authors of the study themselves conclude in their article, "The results of the OHTS do not imply that all individuals with elevated IOP should be treated with ocular hypotensive medication."^3(p708) Others may look at the OHTS results with a "number needed to treat" perspective⁴ and conclude that to prevent glaucoma damage in . . . [Full Text of this Article]

Henry D. Jampel, MD, MHS
Baltimore, Md

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical Practice
Kass et al.
Arch Ophthalmol 2005;123:1021-1022.
FULL TEXT  

Screening for Primary Open-Angle Glaucoma in the Primary Care Setting: An Update for the US Preventive Services Task Force
Fleming et al.
Ann Fam Med 2005;3:167-170.
ABSTRACT | FULL TEXT